- Home
- TGL vs DRMA Comparison
TGL vs DRMA Comparison
Compare TGL & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGL
- DRMA
- Stock Information
- Founded
- TGL 2020
- DRMA 2014
- Country
- TGL United States
- DRMA United States
- Employees
- TGL N/A
- DRMA N/A
- Industry
- TGL Retail: Computer Software & Peripheral Equipment
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- TGL Technology
- DRMA Health Care
- Exchange
- TGL Nasdaq
- DRMA Nasdaq
- Market Cap
- TGL 4.1M
- DRMA 4.5M
- IPO Year
- TGL 2022
- DRMA 2021
- Fundamental
- Price
- TGL $1.27
- DRMA $5.98
- Analyst Decision
- TGL
- DRMA Strong Buy
- Analyst Count
- TGL 0
- DRMA 1
- Target Price
- TGL N/A
- DRMA $30.00
- AVG Volume (30 Days)
- TGL 550.1K
- DRMA 27.4K
- Earning Date
- TGL 08-25-2025
- DRMA 08-13-2025
- Dividend Yield
- TGL N/A
- DRMA N/A
- EPS Growth
- TGL N/A
- DRMA N/A
- EPS
- TGL N/A
- DRMA N/A
- Revenue
- TGL $1,468,790.00
- DRMA N/A
- Revenue This Year
- TGL N/A
- DRMA N/A
- Revenue Next Year
- TGL N/A
- DRMA N/A
- P/E Ratio
- TGL N/A
- DRMA N/A
- Revenue Growth
- TGL N/A
- DRMA N/A
- 52 Week Low
- TGL $0.88
- DRMA $5.74
- 52 Week High
- TGL $116.00
- DRMA $24.90
- Technical
- Relative Strength Index (RSI)
- TGL 59.68
- DRMA 41.48
- Support Level
- TGL $0.97
- DRMA $5.75
- Resistance Level
- TGL $1.32
- DRMA $6.58
- Average True Range (ATR)
- TGL 0.11
- DRMA 0.61
- MACD
- TGL 0.04
- DRMA -0.07
- Stochastic Oscillator
- TGL 88.64
- DRMA 14.56
About TGL Treasure Global Inc.
Treasure Global Inc has created an online-to-offline e-commerce platform business model offering consumers and merchants instant rebates and affiliate cashback programs, while providing a seamless e-payment solution with rebates in both e-commerce and physical retailers/merchant settings. Its product is an internet application branded ZCITY app, that targets consumers by providing personalized deals based on consumers' purchase history, location and preferences.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.